By betting on this "Big Pharma" buyout of a small-cap biotech, one group of investors stands to earn more than 10 times their money. Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and serves as Director of the Investing Daily Wealth Society. He is also the Director of Research at Investing Daily, overseeing the work of our entire analyst team. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms and investment advisors. Jim has a BA in Business Management from The College of William & Mary, and a CFP from the College for Financial Planning.
Analyst Articles
This provider of cloud-based customer management tools lacks sustained profitability and could be ripe for a fall. Read More
The past four years have been good for index investors, but gains were enabled by artificial stimulants. Read More
Even if next year's election goes off without a hitch, privacy issues are likely to dog Facebook and weigh on the stock. Read More
This Thanksgiving, we focus on investment strategies that help you retain the "quality of life" for which you're thankful. Read More
Target has gained 145% since we recommended it two years ago. Here's an investment tactic that could have done even better. Read More
We've recently posted big gains from undervalued stocks. We highlight a beaten-down sector with the potential to deliver even greater profits. Read More
We don't recommend buying stock in Teva Pharmaceutical, but there's a way to profit from Teva even if its share price doesn’t move. Read More
Due to an accounting blunder, NV5 misstated earnings guidance for next year and its stock tanked. Here's how our expert plans to cash in. Read More
Someone loaded up on NXTC fast. Whoever made the trade may get an unfriendly visit from the SEC. Read More